nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3A—mammary gland—sarcoma	0.0127	0.0523	CbGeAlD
Lithium—IMPA2—Teniposide—Etoposide—sarcoma	0.0125	1	CbGdCrCtD
Lithium—IMPA1—hematopoietic system—sarcoma	0.0121	0.0498	CbGeAlD
Lithium—IMPA2—myometrium—sarcoma	0.0106	0.0435	CbGeAlD
Lithium—GSK3B—embryo—sarcoma	0.00999	0.041	CbGeAlD
Lithium—IMPA2—seminal vesicle—sarcoma	0.00956	0.0393	CbGeAlD
Lithium—GSK3A—myometrium—sarcoma	0.00903	0.0371	CbGeAlD
Lithium—GSK3B—hematopoietic system—sarcoma	0.00892	0.0366	CbGeAlD
Lithium—GSK3B—connective tissue—sarcoma	0.00859	0.0353	CbGeAlD
Lithium—IMPA1—lymphoid tissue—sarcoma	0.00853	0.035	CbGeAlD
Lithium—GSK3A—seminal vesicle—sarcoma	0.00816	0.0335	CbGeAlD
Lithium—IMPA2—skin of body—sarcoma	0.0079	0.0325	CbGeAlD
Lithium—GSK3B—smooth muscle tissue—sarcoma	0.00786	0.0323	CbGeAlD
Lithium—GSK3A—connective tissue—sarcoma	0.00747	0.0307	CbGeAlD
Lithium—IMPA2—cardiac atrium—sarcoma	0.0069	0.0284	CbGeAlD
Lithium—GSK3A—smooth muscle tissue—sarcoma	0.00683	0.0281	CbGeAlD
Lithium—GSK3B—uterus—sarcoma	0.00674	0.0277	CbGeAlD
Lithium—IMPA1—testis—sarcoma	0.00664	0.0273	CbGeAlD
Lithium—GSK3B—lymphoid tissue—sarcoma	0.00628	0.0258	CbGeAlD
Lithium—IMPA1—liver—sarcoma	0.00628	0.0258	CbGeAlD
Lithium—IMPA2—tendon—sarcoma	0.00602	0.0247	CbGeAlD
Lithium—GSK3A—cardiac atrium—sarcoma	0.00589	0.0242	CbGeAlD
Lithium—GSK3A—uterus—sarcoma	0.00586	0.0241	CbGeAlD
Lithium—IMPA2—bone marrow—sarcoma	0.00583	0.0239	CbGeAlD
Lithium—GRIA3—testis—sarcoma	0.00564	0.0232	CbGeAlD
Lithium—GRIA3—liver—sarcoma	0.00534	0.0219	CbGeAlD
Lithium—GSK3A—tendon—sarcoma	0.00513	0.0211	CbGeAlD
Lithium—IMPA2—testis—sarcoma	0.00498	0.0205	CbGeAlD
Lithium—GSK3A—bone marrow—sarcoma	0.00497	0.0204	CbGeAlD
Lithium—GSK3B—testis—sarcoma	0.00489	0.0201	CbGeAlD
Lithium—IMPA2—liver—sarcoma	0.00471	0.0193	CbGeAlD
Lithium—GSK3B—liver—sarcoma	0.00462	0.019	CbGeAlD
Lithium—GSK3A—testis—sarcoma	0.00425	0.0175	CbGeAlD
Lithium—GSK3A—liver—sarcoma	0.00402	0.0165	CbGeAlD
Lithium—IMPA2—lymph node—sarcoma	0.00361	0.0148	CbGeAlD
Lithium—GSK3B—lymph node—sarcoma	0.00354	0.0146	CbGeAlD
Lithium—GSK3A—lymph node—sarcoma	0.00308	0.0127	CbGeAlD
Lithium—Psoriasis—Doxorubicin—sarcoma	0.00114	0.00642	CcSEcCtD
Lithium—Folliculitis—Doxorubicin—sarcoma	0.00114	0.00642	CcSEcCtD
Lithium—Swelling—Etoposide—sarcoma	0.00113	0.0064	CcSEcCtD
Lithium—Dehydration—Mitoxantrone—sarcoma	0.00112	0.00631	CcSEcCtD
Lithium—Hypercalcaemia—Epirubicin—sarcoma	0.00111	0.00627	CcSEcCtD
Lithium—Weight increased—Thiotepa—sarcoma	0.0011	0.00618	CcSEcCtD
Lithium—Muscular weakness—Vincristine—sarcoma	0.00109	0.00615	CcSEcCtD
Lithium—Hyperglycaemia—Thiotepa—sarcoma	0.00109	0.00613	CcSEcCtD
Lithium—Nystagmus—Epirubicin—sarcoma	0.00108	0.0061	CcSEcCtD
Lithium—Albuminuria—Epirubicin—sarcoma	0.00104	0.00584	CcSEcCtD
Lithium—Hypercalcaemia—Doxorubicin—sarcoma	0.00103	0.00581	CcSEcCtD
Lithium—Scotoma—Epirubicin—sarcoma	0.00102	0.00574	CcSEcCtD
Lithium—Nystagmus—Doxorubicin—sarcoma	0.001	0.00565	CcSEcCtD
Lithium—Skin ulcer—Epirubicin—sarcoma	0.000993	0.0056	CcSEcCtD
Lithium—Erectile dysfunction—Vincristine—sarcoma	0.000984	0.00555	CcSEcCtD
Lithium—Weight decreased—Vincristine—sarcoma	0.000967	0.00545	CcSEcCtD
Lithium—Hallucination—Thiotepa—sarcoma	0.000959	0.00541	CcSEcCtD
Lithium—Albuminuria—Doxorubicin—sarcoma	0.000958	0.0054	CcSEcCtD
Lithium—Erectile dysfunction—Mitoxantrone—sarcoma	0.000958	0.0054	CcSEcCtD
Lithium—Glycosuria—Epirubicin—sarcoma	0.000954	0.00538	CcSEcCtD
Lithium—Weight increased—Mitoxantrone—sarcoma	0.000947	0.00534	CcSEcCtD
Lithium—Scotoma—Doxorubicin—sarcoma	0.000942	0.00531	CcSEcCtD
Lithium—Weight decreased—Mitoxantrone—sarcoma	0.000941	0.00531	CcSEcCtD
Lithium—Hyperglycaemia—Mitoxantrone—sarcoma	0.000939	0.00529	CcSEcCtD
Lithium—Drowsiness—Mitoxantrone—sarcoma	0.000928	0.00523	CcSEcCtD
Lithium—Skin ulcer—Doxorubicin—sarcoma	0.000919	0.00518	CcSEcCtD
Lithium—Tinnitus—Thiotepa—sarcoma	0.000899	0.00507	CcSEcCtD
Lithium—Glycosuria—Doxorubicin—sarcoma	0.000883	0.00498	CcSEcCtD
Lithium—Arrhythmia—Thiotepa—sarcoma	0.000861	0.00486	CcSEcCtD
Lithium—Alopecia—Thiotepa—sarcoma	0.000852	0.0048	CcSEcCtD
Lithium—Hallucination—Vincristine—sarcoma	0.000851	0.0048	CcSEcCtD
Lithium—Bradycardia—Mitoxantrone—sarcoma	0.000848	0.00478	CcSEcCtD
Lithium—Alopecia—Dactinomycin—sarcoma	0.000846	0.00477	CcSEcCtD
Lithium—Oliguria—Epirubicin—sarcoma	0.000839	0.00473	CcSEcCtD
Lithium—Dysarthria—Epirubicin—sarcoma	0.000817	0.00461	CcSEcCtD
Lithium—Vision blurred—Thiotepa—sarcoma	0.000791	0.00446	CcSEcCtD
Lithium—Coordination abnormal—Epirubicin—sarcoma	0.000787	0.00444	CcSEcCtD
Lithium—Oliguria—Doxorubicin—sarcoma	0.000776	0.00438	CcSEcCtD
Lithium—Agitation—Thiotepa—sarcoma	0.000771	0.00435	CcSEcCtD
Lithium—Dysarthria—Doxorubicin—sarcoma	0.000756	0.00426	CcSEcCtD
Lithium—Alopecia—Vincristine—sarcoma	0.000756	0.00426	CcSEcCtD
Lithium—Salivary hypersecretion—Epirubicin—sarcoma	0.000751	0.00423	CcSEcCtD
Lithium—Arrhythmia—Mitoxantrone—sarcoma	0.000744	0.00419	CcSEcCtD
Lithium—Alopecia—Mitoxantrone—sarcoma	0.000736	0.00415	CcSEcCtD
Lithium—Coordination abnormal—Doxorubicin—sarcoma	0.000729	0.00411	CcSEcCtD
Lithium—Convulsion—Thiotepa—sarcoma	0.000727	0.0041	CcSEcCtD
Lithium—Arthralgia—Thiotepa—sarcoma	0.000715	0.00403	CcSEcCtD
Lithium—Dysgeusia—Mitoxantrone—sarcoma	0.00071	0.004	CcSEcCtD
Lithium—Coma—Epirubicin—sarcoma	0.000707	0.00398	CcSEcCtD
Lithium—Discomfort—Dactinomycin—sarcoma	0.000701	0.00395	CcSEcCtD
Lithium—Salivary hypersecretion—Doxorubicin—sarcoma	0.000695	0.00392	CcSEcCtD
Lithium—Confusional state—Thiotepa—sarcoma	0.000691	0.00389	CcSEcCtD
Lithium—Agitation—Vincristine—sarcoma	0.000684	0.00386	CcSEcCtD
Lithium—Vision blurred—Mitoxantrone—sarcoma	0.000683	0.00385	CcSEcCtD
Lithium—Oedema—Dactinomycin—sarcoma	0.00068	0.00383	CcSEcCtD
Lithium—Hypertonia—Epirubicin—sarcoma	0.000678	0.00382	CcSEcCtD
Lithium—Vertigo—Vincristine—sarcoma	0.000669	0.00377	CcSEcCtD
Lithium—Coma—Doxorubicin—sarcoma	0.000654	0.00369	CcSEcCtD
Lithium—Anorexia—Thiotepa—sarcoma	0.000653	0.00368	CcSEcCtD
Lithium—Anorexia—Dactinomycin—sarcoma	0.000648	0.00365	CcSEcCtD
Lithium—Convulsion—Vincristine—sarcoma	0.000645	0.00364	CcSEcCtD
Lithium—Convulsion—Mitoxantrone—sarcoma	0.000628	0.00354	CcSEcCtD
Lithium—Hypertonia—Doxorubicin—sarcoma	0.000627	0.00354	CcSEcCtD
Lithium—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000624	0.00352	CcSEcCtD
Lithium—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000619	0.00349	CcSEcCtD
Lithium—Arthralgia—Mitoxantrone—sarcoma	0.000617	0.00348	CcSEcCtD
Lithium—Alopecia—Etoposide—sarcoma	0.000612	0.00345	CcSEcCtD
Lithium—Discomfort—Mitoxantrone—sarcoma	0.00061	0.00344	CcSEcCtD
Lithium—Somnolence—Thiotepa—sarcoma	0.000609	0.00343	CcSEcCtD
Lithium—Oedema—Vincristine—sarcoma	0.000608	0.00342	CcSEcCtD
Lithium—Dyspepsia—Thiotepa—sarcoma	0.000603	0.0034	CcSEcCtD
Lithium—Confusional state—Mitoxantrone—sarcoma	0.000597	0.00336	CcSEcCtD
Lithium—Decreased appetite—Thiotepa—sarcoma	0.000596	0.00336	CcSEcCtD
Lithium—Oedema—Mitoxantrone—sarcoma	0.000592	0.00334	CcSEcCtD
Lithium—Decreased appetite—Dactinomycin—sarcoma	0.000591	0.00333	CcSEcCtD
Lithium—Fatigue—Thiotepa—sarcoma	0.000591	0.00333	CcSEcCtD
Lithium—Dysgeusia—Etoposide—sarcoma	0.00059	0.00333	CcSEcCtD
Lithium—Fatigue—Dactinomycin—sarcoma	0.000586	0.0033	CcSEcCtD
Lithium—Shock—Mitoxantrone—sarcoma	0.000582	0.00328	CcSEcCtD
Lithium—Anorexia—Vincristine—sarcoma	0.000579	0.00326	CcSEcCtD
Lithium—Lethargy—Epirubicin—sarcoma	0.000573	0.00323	CcSEcCtD
Lithium—Hypotension—Vincristine—sarcoma	0.000568	0.0032	CcSEcCtD
Lithium—Feeling abnormal—Thiotepa—sarcoma	0.000565	0.00318	CcSEcCtD
Lithium—Anorexia—Mitoxantrone—sarcoma	0.000564	0.00318	CcSEcCtD
Lithium—Feeling abnormal—Dactinomycin—sarcoma	0.00056	0.00316	CcSEcCtD
Lithium—Gastrointestinal pain—Thiotepa—sarcoma	0.00056	0.00316	CcSEcCtD
Lithium—Gastrointestinal pain—Dactinomycin—sarcoma	0.000556	0.00313	CcSEcCtD
Lithium—Musculoskeletal discomfort—Vincristine—sarcoma	0.000553	0.00312	CcSEcCtD
Lithium—Hypotension—Mitoxantrone—sarcoma	0.000553	0.00312	CcSEcCtD
Lithium—Vertigo—Etoposide—sarcoma	0.000542	0.00305	CcSEcCtD
Lithium—Body temperature increased—Thiotepa—sarcoma	0.000542	0.00305	CcSEcCtD
Lithium—Abdominal pain—Thiotepa—sarcoma	0.000542	0.00305	CcSEcCtD
Lithium—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000539	0.00304	CcSEcCtD
Lithium—Body temperature increased—Dactinomycin—sarcoma	0.000538	0.00303	CcSEcCtD
Lithium—Abdominal pain—Dactinomycin—sarcoma	0.000538	0.00303	CcSEcCtD
Lithium—Loss of consciousness—Etoposide—sarcoma	0.00053	0.00299	CcSEcCtD
Lithium—Lethargy—Doxorubicin—sarcoma	0.00053	0.00299	CcSEcCtD
Lithium—Decreased appetite—Vincristine—sarcoma	0.000528	0.00298	CcSEcCtD
Lithium—Ataxia—Epirubicin—sarcoma	0.000528	0.00298	CcSEcCtD
Lithium—Somnolence—Mitoxantrone—sarcoma	0.000526	0.00297	CcSEcCtD
Lithium—Fatigue—Vincristine—sarcoma	0.000524	0.00295	CcSEcCtD
Lithium—Convulsion—Etoposide—sarcoma	0.000522	0.00295	CcSEcCtD
Lithium—Dehydration—Epirubicin—sarcoma	0.000522	0.00294	CcSEcCtD
Lithium—Dyspepsia—Mitoxantrone—sarcoma	0.000521	0.00294	CcSEcCtD
Lithium—Dry skin—Epirubicin—sarcoma	0.000514	0.0029	CcSEcCtD
Lithium—Decreased appetite—Mitoxantrone—sarcoma	0.000514	0.0029	CcSEcCtD
Lithium—Fatigue—Mitoxantrone—sarcoma	0.00051	0.00288	CcSEcCtD
Lithium—Discomfort—Etoposide—sarcoma	0.000507	0.00286	CcSEcCtD
Lithium—Gastrointestinal pain—Vincristine—sarcoma	0.000497	0.0028	CcSEcCtD
Lithium—Gastritis—Epirubicin—sarcoma	0.000497	0.0028	CcSEcCtD
Lithium—Confusional state—Etoposide—sarcoma	0.000496	0.0028	CcSEcCtD
Lithium—Muscular weakness—Epirubicin—sarcoma	0.000495	0.00279	CcSEcCtD
Lithium—Asthenia—Thiotepa—sarcoma	0.000492	0.00277	CcSEcCtD
Lithium—Ataxia—Doxorubicin—sarcoma	0.000488	0.00275	CcSEcCtD
Lithium—Asthenia—Dactinomycin—sarcoma	0.000488	0.00275	CcSEcCtD
Lithium—Feeling abnormal—Mitoxantrone—sarcoma	0.000488	0.00275	CcSEcCtD
Lithium—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000484	0.00273	CcSEcCtD
Lithium—Dehydration—Doxorubicin—sarcoma	0.000483	0.00272	CcSEcCtD
Lithium—Body temperature increased—Vincristine—sarcoma	0.00048	0.00271	CcSEcCtD
Lithium—Abdominal pain—Vincristine—sarcoma	0.00048	0.00271	CcSEcCtD
Lithium—Dry skin—Doxorubicin—sarcoma	0.000476	0.00268	CcSEcCtD
Lithium—Anorexia—Etoposide—sarcoma	0.000469	0.00264	CcSEcCtD
Lithium—Diarrhoea—Thiotepa—sarcoma	0.000469	0.00264	CcSEcCtD
Lithium—Abdominal pain—Mitoxantrone—sarcoma	0.000468	0.00264	CcSEcCtD
Lithium—Body temperature increased—Mitoxantrone—sarcoma	0.000468	0.00264	CcSEcCtD
Lithium—Diarrhoea—Dactinomycin—sarcoma	0.000465	0.00262	CcSEcCtD
Lithium—Hypotension—Etoposide—sarcoma	0.00046	0.00259	CcSEcCtD
Lithium—Gastritis—Doxorubicin—sarcoma	0.00046	0.00259	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—sarcoma	0.000458	0.00258	CcSEcCtD
Lithium—Dizziness—Thiotepa—sarcoma	0.000453	0.00255	CcSEcCtD
Lithium—Weight increased—Epirubicin—sarcoma	0.000441	0.00249	CcSEcCtD
Lithium—Weight decreased—Epirubicin—sarcoma	0.000439	0.00247	CcSEcCtD
Lithium—Hyperglycaemia—Epirubicin—sarcoma	0.000438	0.00247	CcSEcCtD
Lithium—Somnolence—Etoposide—sarcoma	0.000437	0.00247	CcSEcCtD
Lithium—Asthenia—Vincristine—sarcoma	0.000436	0.00246	CcSEcCtD
Lithium—Vomiting—Thiotepa—sarcoma	0.000436	0.00246	CcSEcCtD
Lithium—Drowsiness—Epirubicin—sarcoma	0.000433	0.00244	CcSEcCtD
Lithium—Vomiting—Dactinomycin—sarcoma	0.000432	0.00244	CcSEcCtD
Lithium—Rash—Thiotepa—sarcoma	0.000432	0.00244	CcSEcCtD
Lithium—Dermatitis—Thiotepa—sarcoma	0.000432	0.00243	CcSEcCtD
Lithium—Headache—Thiotepa—sarcoma	0.000429	0.00242	CcSEcCtD
Lithium—Rash—Dactinomycin—sarcoma	0.000429	0.00242	CcSEcCtD
Lithium—Decreased appetite—Etoposide—sarcoma	0.000428	0.00241	CcSEcCtD
Lithium—Asthenia—Mitoxantrone—sarcoma	0.000424	0.00239	CcSEcCtD
Lithium—Fatigue—Etoposide—sarcoma	0.000424	0.00239	CcSEcCtD
Lithium—Diarrhoea—Vincristine—sarcoma	0.000416	0.00234	CcSEcCtD
Lithium—Weight increased—Doxorubicin—sarcoma	0.000408	0.0023	CcSEcCtD
Lithium—Nausea—Thiotepa—sarcoma	0.000407	0.00229	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—sarcoma	0.000406	0.00229	CcSEcCtD
Lithium—Feeling abnormal—Etoposide—sarcoma	0.000406	0.00229	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—sarcoma	0.000405	0.00228	CcSEcCtD
Lithium—Diarrhoea—Mitoxantrone—sarcoma	0.000405	0.00228	CcSEcCtD
Lithium—Nausea—Dactinomycin—sarcoma	0.000404	0.00228	CcSEcCtD
Lithium—Gastrointestinal pain—Etoposide—sarcoma	0.000402	0.00227	CcSEcCtD
Lithium—Dizziness—Vincristine—sarcoma	0.000402	0.00226	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—sarcoma	0.0004	0.00226	CcSEcCtD
Lithium—Bradycardia—Epirubicin—sarcoma	0.000395	0.00223	CcSEcCtD
Lithium—Abdominal pain—Etoposide—sarcoma	0.000389	0.00219	CcSEcCtD
Lithium—Body temperature increased—Etoposide—sarcoma	0.000389	0.00219	CcSEcCtD
Lithium—Vomiting—Vincristine—sarcoma	0.000386	0.00218	CcSEcCtD
Lithium—Rash—Vincristine—sarcoma	0.000383	0.00216	CcSEcCtD
Lithium—Dermatitis—Vincristine—sarcoma	0.000383	0.00216	CcSEcCtD
Lithium—Headache—Vincristine—sarcoma	0.000381	0.00215	CcSEcCtD
Lithium—Vomiting—Mitoxantrone—sarcoma	0.000376	0.00212	CcSEcCtD
Lithium—Rash—Mitoxantrone—sarcoma	0.000373	0.0021	CcSEcCtD
Lithium—Dermatitis—Mitoxantrone—sarcoma	0.000373	0.0021	CcSEcCtD
Lithium—Headache—Mitoxantrone—sarcoma	0.000371	0.00209	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—sarcoma	0.000366	0.00206	CcSEcCtD
Lithium—Tinnitus—Epirubicin—sarcoma	0.000362	0.00204	CcSEcCtD
Lithium—Nausea—Vincristine—sarcoma	0.000361	0.00203	CcSEcCtD
Lithium—Asthenia—Etoposide—sarcoma	0.000353	0.00199	CcSEcCtD
Lithium—Nausea—Mitoxantrone—sarcoma	0.000351	0.00198	CcSEcCtD
Lithium—Arrhythmia—Epirubicin—sarcoma	0.000347	0.00196	CcSEcCtD
Lithium—Alopecia—Epirubicin—sarcoma	0.000343	0.00193	CcSEcCtD
Lithium—Diarrhoea—Etoposide—sarcoma	0.000337	0.0019	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—sarcoma	0.000335	0.00189	CcSEcCtD
Lithium—Flatulence—Epirubicin—sarcoma	0.000333	0.00188	CcSEcCtD
Lithium—Dysgeusia—Epirubicin—sarcoma	0.000331	0.00187	CcSEcCtD
Lithium—Dizziness—Etoposide—sarcoma	0.000325	0.00183	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—sarcoma	0.000321	0.00181	CcSEcCtD
Lithium—Vision blurred—Epirubicin—sarcoma	0.000319	0.0018	CcSEcCtD
Lithium—Alopecia—Doxorubicin—sarcoma	0.000317	0.00179	CcSEcCtD
Lithium—Vomiting—Etoposide—sarcoma	0.000313	0.00176	CcSEcCtD
Lithium—Agitation—Epirubicin—sarcoma	0.000311	0.00175	CcSEcCtD
Lithium—Rash—Etoposide—sarcoma	0.00031	0.00175	CcSEcCtD
Lithium—Dermatitis—Etoposide—sarcoma	0.00031	0.00175	CcSEcCtD
Lithium—Headache—Etoposide—sarcoma	0.000308	0.00174	CcSEcCtD
Lithium—Flatulence—Doxorubicin—sarcoma	0.000308	0.00174	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—sarcoma	0.000306	0.00173	CcSEcCtD
Lithium—Vertigo—Epirubicin—sarcoma	0.000304	0.00171	CcSEcCtD
Lithium—Syncope—Epirubicin—sarcoma	0.000303	0.00171	CcSEcCtD
Lithium—Loss of consciousness—Epirubicin—sarcoma	0.000297	0.00167	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—sarcoma	0.000295	0.00166	CcSEcCtD
Lithium—Convulsion—Epirubicin—sarcoma	0.000293	0.00165	CcSEcCtD
Lithium—Nausea—Etoposide—sarcoma	0.000292	0.00165	CcSEcCtD
Lithium—Arthralgia—Epirubicin—sarcoma	0.000288	0.00162	CcSEcCtD
Lithium—Agitation—Doxorubicin—sarcoma	0.000287	0.00162	CcSEcCtD
Lithium—Discomfort—Epirubicin—sarcoma	0.000284	0.0016	CcSEcCtD
Lithium—Dry mouth—Epirubicin—sarcoma	0.000281	0.00159	CcSEcCtD
Lithium—Vertigo—Doxorubicin—sarcoma	0.000281	0.00158	CcSEcCtD
Lithium—Syncope—Doxorubicin—sarcoma	0.00028	0.00158	CcSEcCtD
Lithium—Confusional state—Epirubicin—sarcoma	0.000278	0.00157	CcSEcCtD
Lithium—Oedema—Epirubicin—sarcoma	0.000276	0.00156	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—sarcoma	0.000275	0.00155	CcSEcCtD
Lithium—Shock—Epirubicin—sarcoma	0.000271	0.00153	CcSEcCtD
Lithium—Convulsion—Doxorubicin—sarcoma	0.000271	0.00153	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—sarcoma	0.000266	0.0015	CcSEcCtD
Lithium—Discomfort—Doxorubicin—sarcoma	0.000263	0.00148	CcSEcCtD
Lithium—Anorexia—Epirubicin—sarcoma	0.000263	0.00148	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—sarcoma	0.00026	0.00147	CcSEcCtD
Lithium—Hypotension—Epirubicin—sarcoma	0.000258	0.00145	CcSEcCtD
Lithium—Confusional state—Doxorubicin—sarcoma	0.000257	0.00145	CcSEcCtD
Lithium—Oedema—Doxorubicin—sarcoma	0.000255	0.00144	CcSEcCtD
Lithium—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000251	0.00142	CcSEcCtD
Lithium—Shock—Doxorubicin—sarcoma	0.000251	0.00142	CcSEcCtD
Lithium—Somnolence—Epirubicin—sarcoma	0.000245	0.00138	CcSEcCtD
Lithium—Anorexia—Doxorubicin—sarcoma	0.000243	0.00137	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—sarcoma	0.000243	0.00137	CcSEcCtD
Lithium—Decreased appetite—Epirubicin—sarcoma	0.00024	0.00135	CcSEcCtD
Lithium—GSK3A—Signaling by PDGF—HRAS—sarcoma	0.000239	0.000421	CbGpPWpGaD
Lithium—Hypotension—Doxorubicin—sarcoma	0.000239	0.00134	CcSEcCtD
Lithium—Fatigue—Epirubicin—sarcoma	0.000238	0.00134	CcSEcCtD
Lithium—GRIA3—Neuronal System—HRAS—sarcoma	0.000237	0.000418	CbGpPWpGaD
Lithium—GSK3A—Immune System—PLCG1—sarcoma	0.000236	0.000417	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—SRC—sarcoma	0.000236	0.000417	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—VEGFA—sarcoma	0.000236	0.000416	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—EGFR—sarcoma	0.000235	0.000415	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000233	0.00131	CcSEcCtD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—CTNNB1—sarcoma	0.000232	0.00041	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TLE1—sarcoma	0.000231	0.000407	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—KRAS—sarcoma	0.000229	0.000404	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—NRAS—sarcoma	0.000228	0.000403	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MMP2—sarcoma	0.000228	0.000402	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—KRAS—sarcoma	0.000228	0.000402	CbGpPWpGaD
Lithium—Feeling abnormal—Epirubicin—sarcoma	0.000227	0.00128	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—NRAS—sarcoma	0.000227	0.000401	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—SRC—sarcoma	0.000227	0.000401	CbGpPWpGaD
Lithium—Somnolence—Doxorubicin—sarcoma	0.000227	0.00128	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB2—KRAS—sarcoma	0.000227	0.0004	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—HRAS—sarcoma	0.000226	0.000399	CbGpPWpGaD
Lithium—Gastrointestinal pain—Epirubicin—sarcoma	0.000226	0.00127	CcSEcCtD
Lithium—GSK3B—DAP12 signaling—KRAS—sarcoma	0.000226	0.000398	CbGpPWpGaD
Lithium—Dyspepsia—Doxorubicin—sarcoma	0.000225	0.00127	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR in disease—EGFR—sarcoma	0.000225	0.000396	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—EGFR—sarcoma	0.000225	0.000396	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—EGFR—sarcoma	0.000225	0.000396	CbGpPWpGaD
Lithium—GSK3A—Immune System—ATF1—sarcoma	0.000225	0.000396	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—MDM2—sarcoma	0.000224	0.000395	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—EGFR—sarcoma	0.000223	0.000393	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—KRAS—sarcoma	0.000222	0.000392	CbGpPWpGaD
Lithium—Decreased appetite—Doxorubicin—sarcoma	0.000222	0.00125	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR in Cancer—EGFR—sarcoma	0.000221	0.000389	CbGpPWpGaD
Lithium—Fatigue—Doxorubicin—sarcoma	0.00022	0.00124	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—EGFR—sarcoma	0.00022	0.000388	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KIT—sarcoma	0.000219	0.000387	CbGpPWpGaD
Lithium—GSK3B—Disease—NPM1—sarcoma	0.000219	0.000387	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—NRAS—sarcoma	0.000218	0.000385	CbGpPWpGaD
Lithium—GSK3A—Disease—PLCG1—sarcoma	0.000218	0.000385	CbGpPWpGaD
Lithium—Body temperature increased—Epirubicin—sarcoma	0.000218	0.00123	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—sarcoma	0.000218	0.00123	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—HRAS—sarcoma	0.000216	0.000382	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	0.000216	0.000382	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—CTNNB1—sarcoma	0.000216	0.000381	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—FOXO1—sarcoma	0.000213	0.000376	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—HRAS—sarcoma	0.000213	0.000375	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PDGFRB—sarcoma	0.000212	0.000375	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—EGFR—sarcoma	0.000212	0.000375	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—KRAS—sarcoma	0.000212	0.000374	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—KRAS—sarcoma	0.000212	0.000374	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—KRAS—sarcoma	0.000212	0.000374	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KIT—sarcoma	0.000211	0.000372	CbGpPWpGaD
Lithium—Feeling abnormal—Doxorubicin—sarcoma	0.00021	0.00119	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR—KRAS—sarcoma	0.00021	0.000371	CbGpPWpGaD
Lithium—GSK3A—Disease—CXCR4—sarcoma	0.00021	0.00037	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PDGFRA—sarcoma	0.000209	0.000369	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CREB1—sarcoma	0.000209	0.000369	CbGpPWpGaD
Lithium—Gastrointestinal pain—Doxorubicin—sarcoma	0.000209	0.00118	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR in Cancer—KRAS—sarcoma	0.000208	0.000368	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—EGFR—sarcoma	0.000208	0.000367	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—KRAS—sarcoma	0.000208	0.000366	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—JUN—sarcoma	0.000207	0.000366	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—EGFR—sarcoma	0.000207	0.000365	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—HRAS—sarcoma	0.000207	0.000365	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—FOXO1—sarcoma	0.000204	0.000361	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PDGFRB—sarcoma	0.000204	0.00036	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—HRAS—sarcoma	0.000204	0.00036	CbGpPWpGaD
Lithium—Abdominal pain—Doxorubicin—sarcoma	0.000202	0.00114	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—sarcoma	0.000202	0.00114	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—PDGFRA—sarcoma	0.000201	0.000354	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CREB1—sarcoma	0.000201	0.000354	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KDR—sarcoma	0.000199	0.000352	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	0.000199	0.000351	CbGpPWpGaD
Lithium—Asthenia—Epirubicin—sarcoma	0.000198	0.00112	CcSEcCtD
Lithium—GSK3B—B Cell Activation—KRAS—sarcoma	0.000196	0.000347	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KRAS—sarcoma	0.000196	0.000345	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—HRAS—sarcoma	0.000196	0.000345	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—HRAS—sarcoma	0.000195	0.000343	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFC—sarcoma	0.000195	0.000343	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—MYC—sarcoma	0.000194	0.000343	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—HRAS—sarcoma	0.000194	0.000342	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—HRAS—sarcoma	0.000193	0.00034	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—HRAS—sarcoma	0.000192	0.000338	CbGpPWpGaD
Lithium—GSK3B—Disease—ENO2—sarcoma	0.00019	0.000335	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—HRAS—sarcoma	0.000189	0.000333	CbGpPWpGaD
Lithium—Diarrhoea—Epirubicin—sarcoma	0.000189	0.00106	CcSEcCtD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—MYC—sarcoma	0.000188	0.000332	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	0.000188	0.000332	CbGpPWpGaD
Lithium—Asthenia—Doxorubicin—sarcoma	0.000183	0.00103	CcSEcCtD
Lithium—Dizziness—Epirubicin—sarcoma	0.000182	0.00103	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—VEGFA—sarcoma	0.000181	0.00032	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—HRAS—sarcoma	0.00018	0.000318	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	0.00018	0.000318	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—HRAS—sarcoma	0.00018	0.000318	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—HRAS—sarcoma	0.000179	0.000315	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTPRC—sarcoma	0.000179	0.000315	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—CTNNB1—sarcoma	0.000178	0.000314	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—HRAS—sarcoma	0.000177	0.000313	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—HRAS—sarcoma	0.000176	0.000311	CbGpPWpGaD
Lithium—Vomiting—Epirubicin—sarcoma	0.000175	0.000989	CcSEcCtD
Lithium—GSK3B—Signaling by WNT in cancer—MYC—sarcoma	0.000175	0.000308	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CREB1—sarcoma	0.000175	0.000308	CbGpPWpGaD
Lithium—GSK3B—Immune System—PLCG1—sarcoma	0.000175	0.000308	CbGpPWpGaD
Lithium—Diarrhoea—Doxorubicin—sarcoma	0.000175	0.000985	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—SRC—sarcoma	0.000175	0.000308	CbGpPWpGaD
Lithium—Rash—Epirubicin—sarcoma	0.000174	0.000981	CcSEcCtD
Lithium—Dermatitis—Epirubicin—sarcoma	0.000174	0.00098	CcSEcCtD
Lithium—GSK3A—Innate Immune System—MDM2—sarcoma	0.000173	0.000305	CbGpPWpGaD
Lithium—Headache—Epirubicin—sarcoma	0.000173	0.000974	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—HRAS—sarcoma	0.00017	0.000301	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TLE1—sarcoma	0.00017	0.000301	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—sarcoma	0.00017	0.000301	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—MMP2—sarcoma	0.00017	0.0003	CbGpPWpGaD
Lithium—Dizziness—Doxorubicin—sarcoma	0.000169	0.000952	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—NRAS—sarcoma	0.000168	0.000296	CbGpPWpGaD
Lithium—GSK3A—Immune System—FOXO1—sarcoma	0.000168	0.000296	CbGpPWpGaD
Lithium—GSK3A—Immune System—PDGFRB—sarcoma	0.000167	0.000296	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—HRAS—sarcoma	0.000167	0.000295	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—HRAS—sarcoma	0.000166	0.000293	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—MDM2—sarcoma	0.000166	0.000293	CbGpPWpGaD
Lithium—GSK3B—Immune System—ATF1—sarcoma	0.000166	0.000293	CbGpPWpGaD
Lithium—GSK3A—Immune System—PDGFRA—sarcoma	0.000165	0.000291	CbGpPWpGaD
Lithium—Nausea—Epirubicin—sarcoma	0.000164	0.000924	CcSEcCtD
Lithium—GSK3B—Developmental Biology—MMP2—sarcoma	0.000163	0.000287	CbGpPWpGaD
Lithium—Vomiting—Doxorubicin—sarcoma	0.000162	0.000915	CcSEcCtD
Lithium—GSK3B—Innate Immune System—KIT—sarcoma	0.000162	0.000286	CbGpPWpGaD
Lithium—GSK3B—Disease—PLCG1—sarcoma	0.000161	0.000285	CbGpPWpGaD
Lithium—Rash—Doxorubicin—sarcoma	0.000161	0.000907	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—sarcoma	0.000161	0.000906	CcSEcCtD
Lithium—Headache—Doxorubicin—sarcoma	0.00016	0.000901	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	0.00016	0.000282	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—SRC—sarcoma	0.000158	0.000279	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KIT—sarcoma	0.000156	0.000275	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FLT1—sarcoma	0.000155	0.000274	CbGpPWpGaD
Lithium—GSK3B—Disease—CXCR4—sarcoma	0.000155	0.000273	CbGpPWpGaD
Lithium—GSK3A—Disease—FOXO1—sarcoma	0.000155	0.000273	CbGpPWpGaD
Lithium—GSK3A—Disease—PDGFRB—sarcoma	0.000155	0.000273	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CREB1—sarcoma	0.000154	0.000272	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—VEGFA—sarcoma	0.000154	0.000272	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—EGFR—sarcoma	0.000153	0.00027	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PLCG1—sarcoma	0.000153	0.00027	CbGpPWpGaD
Lithium—GSK3A—Disease—PDGFRA—sarcoma	0.000152	0.000269	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—NRAS—sarcoma	0.000152	0.000268	CbGpPWpGaD
Lithium—Nausea—Doxorubicin—sarcoma	0.000152	0.000855	CcSEcCtD
Lithium—GSK3A—Innate Immune System—JUN—sarcoma	0.00015	0.000265	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CTNNB1—sarcoma	0.000149	0.000263	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CREB1—sarcoma	0.000148	0.000262	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCR4—sarcoma	0.000147	0.000259	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ATF1—sarcoma	0.000145	0.000256	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—sarcoma	0.000145	0.000255	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—MYC—sarcoma	0.000144	0.000254	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFC—sarcoma	0.000144	0.000254	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—sarcoma	0.000138	0.000244	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—sarcoma	0.000137	0.000242	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—SRC—sarcoma	0.000135	0.000238	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—sarcoma	0.000131	0.000231	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CTNNB1—sarcoma	0.00013	0.00023	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NRAS—sarcoma	0.00013	0.000229	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—SRC—sarcoma	0.000129	0.000228	CbGpPWpGaD
Lithium—GSK3A—Immune System—KIT—sarcoma	0.000128	0.000226	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MDM2—sarcoma	0.000128	0.000225	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CTNNB1—sarcoma	0.000125	0.00022	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NRAS—sarcoma	0.000124	0.00022	CbGpPWpGaD
Lithium—GSK3B—Immune System—FOXO1—sarcoma	0.000124	0.000219	CbGpPWpGaD
Lithium—GSK3B—Immune System—PDGFRB—sarcoma	0.000124	0.000218	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—sarcoma	0.000123	0.000217	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—MDM2—sarcoma	0.000123	0.000216	CbGpPWpGaD
Lithium—GSK3B—Immune System—PDGFRA—sarcoma	0.000122	0.000215	CbGpPWpGaD
Lithium—GSK3A—Immune System—CREB1—sarcoma	0.000122	0.000215	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—sarcoma	0.000118	0.000208	CbGpPWpGaD
Lithium—GSK3A—Disease—KIT—sarcoma	0.000118	0.000208	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FLT1—sarcoma	0.000115	0.000203	CbGpPWpGaD
Lithium—GSK3B—Disease—FOXO1—sarcoma	0.000114	0.000202	CbGpPWpGaD
Lithium—GSK3B—Disease—PDGFRB—sarcoma	0.000114	0.000202	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF1R—sarcoma	0.000114	0.000201	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—sarcoma	0.000113	0.0002	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PLCG1—sarcoma	0.000113	0.000199	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—SRC—sarcoma	0.000113	0.000199	CbGpPWpGaD
Lithium—GSK3B—Disease—PDGFRA—sarcoma	0.000112	0.000198	CbGpPWpGaD
Lithium—GSK3A—Disease—CREB1—sarcoma	0.000112	0.000198	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—sarcoma	0.000112	0.000197	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—sarcoma	0.000111	0.000196	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—JUN—sarcoma	0.000111	0.000196	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CTNNB1—sarcoma	0.00011	0.000194	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—sarcoma	0.00011	0.000194	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCR4—sarcoma	0.000109	0.000192	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NRAS—sarcoma	0.000108	0.000191	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FOXO1—sarcoma	0.000108	0.000191	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PDGFRB—sarcoma	0.000108	0.000191	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ATF1—sarcoma	0.000107	0.000189	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—sarcoma	0.000107	0.000189	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PDGFRA—sarcoma	0.000107	0.000188	CbGpPWpGaD
Lithium—GSK3A—Immune System—MDM2—sarcoma	0.000101	0.000178	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—SRC—sarcoma	9.96e-05	0.000176	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—sarcoma	9.88e-05	0.000174	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—sarcoma	9.58e-05	0.000169	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—SRC—sarcoma	9.56e-05	0.000169	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—sarcoma	9.48e-05	0.000167	CbGpPWpGaD
Lithium—GSK3B—Immune System—KIT—sarcoma	9.44e-05	0.000167	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—sarcoma	9.34e-05	0.000165	CbGpPWpGaD
Lithium—GSK3A—Disease—MDM2—sarcoma	9.29e-05	0.000164	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—sarcoma	9.2e-05	0.000162	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—sarcoma	9.11e-05	0.000161	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—sarcoma	8.99e-05	0.000159	CbGpPWpGaD
Lithium—GSK3B—Immune System—CREB1—sarcoma	8.99e-05	0.000159	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KDR—sarcoma	8.97e-05	0.000158	CbGpPWpGaD
Lithium—GSK3A—Immune System—JUN—sarcoma	8.75e-05	0.000154	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—sarcoma	8.73e-05	0.000154	CbGpPWpGaD
Lithium—GSK3B—Disease—KIT—sarcoma	8.72e-05	0.000154	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTNNB1—sarcoma	8.68e-05	0.000153	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1R—sarcoma	8.42e-05	0.000149	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—sarcoma	8.38e-05	0.000148	CbGpPWpGaD
Lithium—GSK3B—Disease—CREB1—sarcoma	8.3e-05	0.000146	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KIT—sarcoma	8.26e-05	0.000146	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—sarcoma	8.24e-05	0.000146	CbGpPWpGaD
Lithium—GSK3A—Disease—CTNNB1—sarcoma	8.02e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FOXO1—sarcoma	8.01e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDGFRB—sarcoma	8e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—sarcoma	7.93e-05	0.00014	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—sarcoma	7.92e-05	0.00014	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDGFRA—sarcoma	7.88e-05	0.000139	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CREB1—sarcoma	7.87e-05	0.000139	CbGpPWpGaD
Lithium—GSK3A—Immune System—SRC—sarcoma	7.85e-05	0.000139	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—sarcoma	7.55e-05	0.000133	CbGpPWpGaD
Lithium—GSK3B—Immune System—MDM2—sarcoma	7.44e-05	0.000131	CbGpPWpGaD
Lithium—GSK3A—Disease—SRC—sarcoma	7.25e-05	0.000128	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—sarcoma	7.01e-05	0.000124	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—sarcoma	6.97e-05	0.000123	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—sarcoma	6.88e-05	0.000121	CbGpPWpGaD
Lithium—GSK3B—Disease—MDM2—sarcoma	6.87e-05	0.000121	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—sarcoma	6.73e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—sarcoma	6.65e-05	0.000117	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KDR—sarcoma	6.63e-05	0.000117	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MDM2—sarcoma	6.51e-05	0.000115	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—sarcoma	6.5e-05	0.000115	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—sarcoma	6.49e-05	0.000115	CbGpPWpGaD
Lithium—GSK3B—Immune System—JUN—sarcoma	6.47e-05	0.000114	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTNNB1—sarcoma	6.42e-05	0.000113	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—sarcoma	6.35e-05	0.000112	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KIT—sarcoma	6.11e-05	0.000108	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—sarcoma	6e-05	0.000106	CbGpPWpGaD
Lithium—GSK3B—Disease—CTNNB1—sarcoma	5.92e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—sarcoma	5.82e-05	0.000103	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CREB1—sarcoma	5.81e-05	0.000103	CbGpPWpGaD
Lithium—GSK3B—Immune System—SRC—sarcoma	5.8e-05	0.000102	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—sarcoma	5.67e-05	0.0001	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JUN—sarcoma	5.66e-05	9.98e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNB1—sarcoma	5.61e-05	9.91e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—sarcoma	5.58e-05	9.85e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—sarcoma	5.52e-05	9.75e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—SRC—sarcoma	5.35e-05	9.45e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—sarcoma	5.15e-05	9.09e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—sarcoma	5.1e-05	9e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—sarcoma	5.08e-05	8.97e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SRC—sarcoma	5.07e-05	8.95e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—sarcoma	4.94e-05	8.72e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—sarcoma	4.88e-05	8.61e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MDM2—sarcoma	4.81e-05	8.49e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—sarcoma	4.8e-05	8.47e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—sarcoma	4.8e-05	8.47e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—sarcoma	4.69e-05	8.28e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—sarcoma	4.55e-05	8.02e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—sarcoma	4.45e-05	7.85e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—sarcoma	4.43e-05	7.82e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—sarcoma	4.3e-05	7.58e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—sarcoma	4.2e-05	7.41e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—sarcoma	4.19e-05	7.39e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JUN—sarcoma	4.18e-05	7.38e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNB1—sarcoma	4.15e-05	7.32e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—sarcoma	4.08e-05	7.2e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—sarcoma	3.77e-05	6.65e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SRC—sarcoma	3.75e-05	6.62e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—sarcoma	3.73e-05	6.59e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—sarcoma	3.65e-05	6.44e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—sarcoma	3.61e-05	6.37e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—sarcoma	3.57e-05	6.3e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—sarcoma	3.36e-05	5.93e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—sarcoma	3.29e-05	5.8e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—sarcoma	3.1e-05	5.48e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—sarcoma	2.76e-05	4.87e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—sarcoma	2.64e-05	4.66e-05	CbGpPWpGaD
